ClinVar Miner

Submissions for variant NM_000251.2(MSH2):c.212-1G>A (rs267607914)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 7
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
International Society for Gastrointestinal Hereditary Tumours (InSiGHT) RCV000076394 SCV000107430 pathogenic Lynch syndrome 2013-09-05 reviewed by expert panel research Multifactorial likelihood analysis posterior probability >0.99
Ambry Genetics RCV000218216 SCV000278680 pathogenic Hereditary cancer-predisposing syndrome 2018-03-13 criteria provided, single submitter clinical testing Alterations at the canonical donor/acceptor sites (+/- 1, 2) without other strong (b-level) evidence supporting pathogenicity;Detected in individual satisfying established diagnostic critera for classic disease without a clear mutation
GeneDx RCV000202270 SCV000567721 pathogenic not provided 2017-08-29 criteria provided, single submitter clinical testing This pathogenic variant is denoted MSH2 c.212-1G>A or IVS1-1G>A and consists of a G>A nucleotide substitution at the -1 position of intron 1 of the MSH2 gene. The variant destroys a canonical splice acceptor site and is predicted to cause abnormal gene splicing, leading to either an abnormal message that is subject to nonsense-mediated mRNA decay or to an abnormal protein product. This variant has been observed in at least three individuals with Lynch syndrome (Overbeek 2007, Ramsoekh 2008, De Lellis 2013), and is considered pathogenic.
Invitae RCV000696322 SCV000824877 pathogenic Hereditary nonpolyposis colorectal neoplasms 2019-05-21 criteria provided, single submitter clinical testing This sequence change affects an acceptor splice site in intron 1 of the MSH2 gene. It is expected to disrupt RNA splicing and likely results in an absent or disrupted protein product. This variant is not present in population databases (ExAC no frequency). This variant has been observed in several individuals affected with Lynch syndrome-associated cancers (PMID: 17453009, 18625694, 20591884, 24278394, 29568967). ClinVar contains an entry for this variant (Variation ID: 90892). Experimental studies have shown that this variant disrupts mRNA splicing (PMID: 29568967). Donor and acceptor splice site variants typically lead to a loss of protein function (PMID: 16199547), and loss-of-function variants in MSH2 are known to be pathogenic (PMID: 15849733, 24362816). For these reasons, this variant has been classified as Pathogenic.
Color RCV000218216 SCV001348701 pathogenic Hereditary cancer-predisposing syndrome 2019-11-13 criteria provided, single submitter clinical testing
Mayo Clinic Genetic Testing Laboratories,Mayo Clinic RCV000202270 SCV000257169 pathogenic not provided no assertion criteria provided research
Constitutional Genetics Lab,Leon Berard Cancer Center RCV001250032 SCV001423957 pathogenic Lynch-like syndrome 2019-07-01 no assertion criteria provided clinical testing

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.